{'fraction_non_alphanumeric': 0.04873949579831933, 'fraction_numerical': 0.015126050420168067, 'mean_word_length': 4.96, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Letter to the editor: Standardization of HBV‐RNA assay for the different phases of chronic hepatitis B is essential

We read with interest the article by Mak et al. (1) that assessed HBV-RNA profiles using real-time PCR (m2000 system, Abbott Diagnostics, Abbott Park, USA), and their correlation with other viral biomarkers, in a large cohort of chronic hepatitis-B (CHB) patients, either treatment-naïve or receiving nucleos(t)ide analogues. The authors reported median serum levels of HBV-DNA higher than HBV-RNA by 1-2 log10 in both HBeAg-positive and HBeAg-negative treatment-naïve patients.